Correlation between TSP-1, TGF-β and PPAR-γ expression levels and glioma microvascular density

Zhang,Jing; Yang,Wei; Zhao,Duanyun; Han,Yun; Liu,Bo; Zhao,Hua; Wang,Hongbo; Zhang,Quanzhong; Xu,Guangming

doi:10.3892/ol.2013.1650

Correlation between TSP-1, TGF-β and PPAR-γ expression levels and glioma microvascular density

Authors:
- Jing Zhang
- Wei Yang
- Duanyun Zhao
- Yun Han
- Bo Liu
- Hua Zhao
- Hongbo Wang
- Quanzhong Zhang
- Guangming Xu
View Affiliations

Affiliations: Department of Neurosurgery, Shandong University, Jinan, Shandong 250100, P.R. China, Department of Neurosurgery, Shandong Provincial Hospital, Jinan, Shandong 250014, P.R. China, Department of Neurosurgery, Heze Municipal Hospital, Heze, Shandong 274000, P.R. China
Published online on: October 29, 2013 https://doi.org/10.3892/ol.2013.1650
Pages: 95-100

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gliomas are the most common type of primary tumor in the central nervous system and are characterized by abundant capillary angiogenesis. It is important to study the underlying molecular mechanisms of angiogenesis in order to aid the identification of potential therapeutic targets. The aim of the current study was to investigate the expression levels of thrombospondin-1 (TSP-1), transforming growth factor-β (TGF-β) and peroxisome proliferator-activated receptor-γ (PPAR-γ) in gliomas, and determine their relationships with angiogenesis. Immunohistochemical methods were used to detect TSP-1, TGF-β and PPAR-γ expression levels and to assess microvascular density (MVD) in 99 glioma tissue samples of various grades. The total positive expression rates of TSP-1 and PPAR-γ were 78.4 and 94.1% in low-grade gliomas and 45.8 and 39.6% in high‑grade gliomas. These values suggest that their expression negatively correlated with tumor grade. However, TGF-β expression positively correlated with tumor grade; the total positive expression rate of TGF-β in high‑grade gliomas (93.8%) was significantly increased compared with that in low-grade gliomas (43.1%). The MVD in the low‑grade group was 28±7.2 vessels/field, which was significantly lower than in the high-grade group (45±6.2 vessels/field). TSP-1 and PPAR-γ expression levels were negatively correlated with MVD (P<0.05), while the TGF-β expression level was positively correlated with MVD (P<0.05). These results indicate that the TSP-1, TGF-β and PPAR-γ expression levels in gliomas are correlated with MVD, which suggests that these proteins may be involved in the regulation of glioma angiogenesis.

View Figures

View References

1	Crawford SE, Stellmach V, Murphy-Ullrich JE, et al: Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell. 93:1159–1170. 1998. View Article : Google Scholar : PubMed/NCBI
2	Presser LD, Haskett A and Waris G: Hepatitis C virus-induced furin and thrombospondin-1 activate TGF-β1: role of TGF-β1 in HCV replication. Virology. 412:284–296. 2011.PubMed/NCBI
3	Recouvreux MV, Camilletti MA, Rifkin DB, Becu-Villalobos D and Diaz-Torga G: Thrombospondin-1 (TSP-1) analogs ABT-510 and ABT-898 inhibit prolactinoma growth and recover active pituitary transforming growth factor-β1 (TGF-β1). Endocrinology. 153:3861–3871. 2012.PubMed/NCBI
4	Hayashi H, Sakai K, Baba H and Sakai T: Thrombospondin-1 is a novel negative regulator of liver regeneration after partial hepatectomy through transforming growth factor-beta1 activation in mice. Hepatology. 55:1562–1573. 2012. View Article : Google Scholar
5	Nakao T, Kurita N, Komatsu M, et al: Expression of thrombospondin-1 and Ski are prognostic factors in advanced gastric cancer. Int J Clin Oncol. 16:145–152. 2011. View Article : Google Scholar
6	Punekar S, Zak S, Kalter VG, et al: Thrombospondin 1 and its mimetic peptide ABT-510 decrease angiogenesis and inflammation in a murine model of inflammatory bowel disease. Pathobiology. 75:9–21. 2008. View Article : Google Scholar : PubMed/NCBI
7	Reka AK, Kurapati H, Narala VR, et al: Peroxisome proliferator-activated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition. Mol Cancer Ther. 9:3221–3232. 2010. View Article : Google Scholar
8	Dong YW, Wang XP and Wu K: Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor gamma involves angiogenesis inhibition. World J Gastroenterol. 15:441–448. 2009. View Article : Google Scholar
9	Shigeto T, Yokoyama Y, Xin B and Mizunuma H: Peroxisome proliferator-activated receptor alpha and gamma ligands inhibit the growth of human ovarian cancer. Oncol Rep. 18:833–840. 2007.
10	Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97–109. 2007. View Article : Google Scholar
11	Wang-Rodriguez J, Urquidi V, Rivard A and Goodison S: Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status. Breast Cancer Res. 5:R136–R143. 2003. View Article : Google Scholar
12	Aspiotis M, Tsanou E, Gorezis S, et al: Angiogenesis in pterygium: study of microvessel density, vascular endothelial growth factor, and thrombospondin-1. Eye (Lond). 21:1095–1101. 2007. View Article : Google Scholar
13	Karavasilis V, Malamou-Mitsi V, Briasoulis E, Tsanou E, Kitsou E and Pavlidis N: Clinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinoma. Int J Gynecol Cancer. 16(Suppl 1): 241–246. 2006. View Article : Google Scholar
14	Baltaci S, Orhan D, Göğüs C, Filiz E, Tulunay O and Göğüs O: Thrombospondin-1, vascular endothelial growth factor expression and microvessel density in renal cell carcinoma and their relationship with multifocality. Eur Urol. 44:76–81. 2003. View Article : Google Scholar
15	Hyder SM, Liang Y and Wu J: Estrogen regulation of thrombospondin-1 in human breast cancer cells. Int J Cancer. 125:1045–1053. 2009. View Article : Google Scholar : PubMed/NCBI
16	Fitchev PP, Wcislak SM, Lee C, et al: Thrombospondin-1 regulates the normal prostate in vivo through angiogenesis and TGF-beta activation. Lab Invest. 90:1078–1090. 2010. View Article : Google Scholar : PubMed/NCBI
17	Byrne GJ, Hayden KE, McDowell G, et al: Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer. Int J Oncol. 31:1127–1132. 2007.
18	Elpek GO, Gokhan GA and Bozova S: Thrombospondin-1 expression correlates with angiogenesis in experimental cirrhosis. World J Gastroenterol. 14:2213–2217. 2008. View Article : Google Scholar
19	Jiang M, Mou CZ, Han T, Wang M and Yang W: Thrombospondin-1 and transforming growth factor-β1 levels in prolactinoma and their clinical significance. J Int Med Res. 40:1284–1294. 2012.
20	Fontana A, Filleur S, Guglielmi J, et al: Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo. Int J Cancer. 116:686–691. 2005. View Article : Google Scholar : PubMed/NCBI
21	Kaygusuz G, Tulunay O, Baltaci S and Gogus O: Microvessel density and regulators of angiogenesis in malignant and nonmalignant prostate tissue. Int Urol Nephrol. 39:841–850. 2007. View Article : Google Scholar : PubMed/NCBI
22	Pardali K and Moustakas A: Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta. 1775:21–62. 2007.PubMed/NCBI
23	Karavasilis V, Malamou-Mitsi V, Briasoulis E, et al: Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1. BMC Cancer. 5:252005. View Article : Google Scholar : PubMed/NCBI
24	Kasper HU, Ebert M, Malfertheiner P, Roessner A, Kirkpatrick CJ and Wolf HK: Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density. Virchows Arch. 438:116–120. 2001. View Article : Google Scholar : PubMed/NCBI
25	Li Y, Wen X, Spataro BC, Hu K, Dai C and Liu Y: Hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists. J Am Soc Nephrol. 17:54–65. 2006. View Article : Google Scholar
26	Boyer JF, Balard P, Authier H, et al: Tumor necrosis factor alpha and adalimumab differentially regulate CD36 expression in human monocytes. Arthritis Res Ther. 9:R222007. View Article : Google Scholar : PubMed/NCBI